Oslo, Norway
Oslo, Norway
SEARCH FILTERS
Time filter
Source Type

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES Bionor Pharma ASA (OSE: BIONOR) has entered into an agreement to acquire the entire share capital of Solon Eiendom AS ("Solon Eiendom") for a total consideration of approximately NOK 1,000 million (the "Acquisition") settled by issuing 6,666,666,666 new shares (the "Consideration Shares") in Bionor Pharma ASA ("Bionor" or the "Company") at NOK 0.15 per share to the sellers of Solon Eiendom, Alden AS, Dukat AS, Hortulan AS, John Galt Invest AS, MRD Holding AS and Solon AS (the "Solon Shareholders"). Solon Eiendom is a leading residential property developer in the Oslo region that delivers high quality housing. As a consequence of the new significant business area, the Company plans to change its existing management and, subject to a successful completion of the Acquisition, consider proposing changes to the Board of Directors. The current intention is to propose that Andreas Martinussen, the current Chief Executive Officer of Solon Eiendom, shall be appointed as the Chief Executive Officer for Bionor and Tarjei Røise Warholm shall be appointed as Chief Financial Officer. The existing Chairman of the Board of Directors of Solon Eiendom, Simen Thorsen, will be proposed as the new Chairman of the Board of Directors. Einar J. Greve, the current Chairman of the Board of Directors of the Company will be proposed as Vice Chairman of the Board of Directors, and Tore Aksel Voldberg, Bente Bøhler and Katarina Finneng will be proposed as board members. It will also be proposed that Bionor changes name to Solon Eiendom ASA. Please find attached an updated company presentation that further presents the new business area of Company. In Q3 2016, Bionor put all preparatory activities of the planned clinical program on hold and initiated a strategic review of Vacc-4x, and the clinical development plan to ensure it is up to date going forward. For this Bionor has engaged a group of highly experienced international HIV scientific, clinical and commercial experts to propose updated development plans going forward. This process is currently ongoing and is done in close collaboration with the company. The same expert group is engaged in the strategic partnership assessment. In order to finance the acquisition of a minority stake in a property project in Ski for approximately NOK 60 million, acquisition of land for new projects and for general corporate purposes, Bionor intends to carry out a private placement of 1,000,000,000 new shares at NOK 0.15 per share with gross proceeds of NOK 150 million and in addition, the Solon Shareholders intends sell down 1,000,000,000 Consideration Shares at NOK 0.15 per share (the "Private Placement"). Dukat AS (owned by Tore Aksel Voldberg), MRD Holding AS (owned by Simen Thorsen) and Solon AS (owned by Tore Aksel Voldberg) will sell 333,333,333, 333,333,334 and 333,333,333 Consideration Shares, respectively. The Private Placement is planned to be executed before 16 December 2016 and will be directed at Norwegian and international professional investors and have a minimum subscription amount of the NOK equivalent of EUR 100,000. In addition the Company plans to carry out a rights issue of 666,666,666 new shares at NOK 0.15 per share directed at existing shareholders of Bionor that does not participate in the Private Placement (the "Subsequent Offering") and who are not resident in a jurisdiction where such offering would be unlawful, or for jurisdictions other than Norway, which would require any filing, registration or similar action. The Company intends to seek listing for the subscription rights for the Subsequent Offering. The Private Placement and the Subsequent Offering are fully underwritten. The Company has engaged Arctic Securities AS, DNB Markets, a part of DNB Bank ASA, and Sparebank 1 Markets as managers for the Private Placement and the Subsequent Offering (the "Managers"). The Private Placement and the Subsequent Offering are fully underwritten by a group of Norwegian and international institutional investors and family offices , and existing shareholders of the Company, including companies associated with the Company's largest shareholder, Ferncliff Listed Dai, and Cipriano AS, controlled by the chairman of the Board of Directors, Einar J. Greve (the "Underwriters"). The Underwriters will receive an underwriting fee of approximately NOK 5 million in the aggregate from the Company and NOK 3 million in aggregate from the Selling Shareholders, and the Underwriters are guaranteed allocation of Offer Shares in the Private Placement for an amount corresponding to the lower of (i) 50% of its underwriting obligation in respect of the Private Placement, and (ii) 50% of the number of shares which the guarantor has applied subscription for in the Private Placement. Completion of the Acquisition, the Private Placement and the Subsequent Offering, is subject to, among other things, approval by the shareholders of the Company at an extraordinary general meeting (the "EGM") which is scheduled for on or about 14 December 2016. The notice for the EGM will be sent to the shareholders in due course. The largest shareholders of the Company, including Ferncliff Listed Dai, Lars H. Høie, Cipriano AS and Alden AS, have signed a lock-up undertaking until the EGM and have undertaken to vote in favour of such resolutions at the EGM. Following the issuance of the Consideration Shares, the Private Placement and the Subsequent Offering, the Solon Shareholders will own approximately 58 per cent of the Company. The Solon Shareholders have undertaken a lock-up of 12 months to the Managers, subject to certain conditions. The Acquisition of Solon Eiendom is expected to be completed in due course, and as soon as practicably possible following the EGM, i.e. in December 2016. In addition to the foregoing EGM approval of the Acquisition and the Private Placement, the closing of the Acquisition is subject to certain customary closing conditions for transactions of this kind, but the transaction is not subject to regulatory approval. "Solon Eiendom is a residential property developer that operates in the Oslo region. It has a solid track-record and a highly experienced management team. Based on Solon Eiendom's land bank and ongoing projects, the Company is set for growth and consequently we believe this acquisition will be an important step for the Company to create shareholder value", says Einar J. Greve, Chairman of the Board of Directors. In connection with the Acquisition, the CFO of Solon Eiendom, Tarjei Røise Warholm, will receive a cash bonus of NOK 100,000. Further, Solon Eiendom's current agreement with CEO Andreas Martinussen has been renegotiated, subject to completion of the Acquisition. Finally, the Company has been entered into an agreement with Cipriano AS, in which the latter has through the chairman Einar J. Greve acted as an strategic advisor in connection with the Acquisition and Private Placement and is entitled to a project fee of NOK 3 million (excluding VAT), subject to completion of the Acquisition. For more information, please contact: About Solon Eiendom Solon Eiendom is a Norwegian residential real estate development company focusing on the Oslo and Akershus region. Solon Eiendom was established in 2006 by founder Simen Thorsen and investor Tore Aksel Voldberg. The company has since its incorporation delivered 570 units with a corresponding sales value of close to NOK ~3 billion and sold more than 800 units with a total sales price of more than NOK ~4 billion. Solon Eiendom delivered revenues of approximately NOK 241 million (NGAAP), NOK 328 million (NGAAP) and NOK 805 million (NGAAP) in 2013, 2014 and 2015, respectively. Solon Eiendom delivered EBIT of NOK 20 million (NGAAP), NOK 50 million (NGAAP) and NOK 115 million (NGAAP) in 2013, 2014 and 2015, respectively. Solon Eiendom had total assets of NOK 602 million (NGAAP), NOK 817 million (NGAAP), NOK 1,376 million (NGAAP) in 2013, 2014 and 2015, respectively. The current Board of Directors of Solon Eiendom consists of Simen Thorsen and Tore Aksel Voldberg. The executive management of Solon Eiendom is CEO Andreas Martinussen, CFO Tarjei Røise Warholm, and the company has in total 16 employees. Solon Eiendom is currently owned by Alden AS (15 per cent), Dukat AS (14 per cent), Hortulan AS (22 per cent), John Galt Invest AS (2 per cent), MRD Holding AS (18 per cent) and Solon AS (29 per cent). About Bionor Bionor's mission is to enable the immune system to fight HIV infection. Bionor is the first company, which has successfully completed a clinical trial using the shock and kill approach, thereby creating a strong foundation for further advancing its therapeutic vaccine Vacc-4x in combination with other agents towards a functional cure. The company believes it has first mover potential based on clinical results to date and early adoption of the shock and kill strategy. In December 2015, Bionor announced that the HIV trial REDUC with Vacc-4x and romidepsin successfully met its primary endpoint by reducing latent HIV reservoir and further demonstrated control of viral load. Bionor currently retains full ownership rights to the HIV immunotherapy Vacc-4x, i.e., the upside potential from partnering or licensing remains with the company's shareholders. Bionor is listed on Oslo Børs (OSE: BIONOR). More information about Bionor is available at www.bionorpharma.com.


News Article | November 23, 2016
Site: globenewswire.com

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANYOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.             BIONOR PHARMA - CONTEMPLATED PRIVATE PLACEMENT Reference is made to the stock exchange notice 21 November 2016 where Bionor Pharma ASA ("Bionor" or the "Company") announced the acquisition of Solon Eiendom AS ("Solon Eiendom") for a total consideration of approximately NOK 1,000 million (the "Acquisition") to be settled by issuing 6,666,666,666 new shares (the "Consideration Shares") in Bionor at NOK 0.15 per share, a fully underwritten private placement of 1,000,000,000 new shares at NOK 0.15 per share and 1,000,000,000 Consideration Shares at NOK 0.15 per share and a subsequent offering of 666,666,666 new shares at NOK 0.15 per share directed at existing shareholders of Bionor that does not participate in the Private Placement (the "Subsequent Offering") and who are not resident in a jurisdiction where such offering would be unlawful, or for jurisdictions other than Norway, which would require any filing, registration or similar action. The Company has engaged Arctic Securities AS, DNB Markets, a part of DNB Bank ASA, and SpareBank 1 Markets as managers for the Private Placement and the Subsequent Offering (the "Managers"). The application period for the Private Placement opens today at 16:30 CET and closes 24 November 2016 at 08:00 CET. The Managers may, however, at any time resolve to close or extend the bookbuilding period at its sole discretion. The minimum subscription and allocation amount in the Private Placement will be the NOK equivalent of EUR 100,000, provided that the Company may, at its sole discretion, allocate an amount below EUR 100,000 to the extent applicable exemptions from the prospectus requirement pursuant to applicable regulations, including the Norwegian Securities Trading Act and ancillary regulations, are available. The final allocation and completion of the Private Placement is subject to approval by the Company's Board of Directors. The Private Placement will be directed towards Norwegian investors and international institutional investors, in each case subject to and in compliance with applicable exemptions from relevant prospectus or registration requirements. The Board, together with the Company's management and the Managers, has considered various transaction alternatives to secure new financing. Based on an overall assessment, taking into account inter alia the need for funding, execution risk and possible alternatives, the Board has on the basis of careful considerations decided that the Private Placement combined with the Subsequent Offering is the alternative that best protects the Company's and the shareholders' joint interests. Thus, the waiver of the preferential rights inherent in a share capital increase through issuance of new shares is considered necessary. The Company will receive gross proceeds of NOK 150 million from the Private Placement. The net proceeds from the Private Placement will be used for acquisition of a minority stake currently owned by Edvin Austbø (who is an indirect shareholder of Solon Eiendom) in a property project in Ski for approximately NOK 60 million, acquisition of land for new projects and for general corporate purposes. Certain existing shareholders of Solon Eiendom (the "Selling Shareholders") will sell down 1,000,000,000 Consideration Shares at NOK 0.15 per share as part of the Private Placement. Dukat AS (owned by Tore Aksel Voldberg), MRD Holding AS (owned by Simen Thorsen) and Solon AS (owned by Tore Aksel Voldberg) will sell 333,333,333, 333,333,334 and 333,333,333 Consideration Shares, respectively. Subsequent to the Private Placement and completion of the Acquisition, the Company plans to carry out a subsequent offering of 666,666,666 new shares at NOK 0.15 per share directed at existing shareholders of Bionor that does not participate in the Private Placement (the "Subsequent Offering") and who are not resident in a jurisdiction where such offering would be unlawful, or for jurisdictions other than Norway, which would require any filing, registration or similar action. The Company intends to seek listing for the subscription rights for the Subsequent Offering. The Company will provide additional information about the Subsequent Offering in due course. The Private Placement and the Subsequent Offering are fully underwritten by a group of Norwegian and international institutional investors and family offices, and existing shareholders of the Company, including Ferncliff Listed Dai AS, a company associated with the Company's largest shareholder and member of Board of Directors, Øystein Stray Spetalen, and Cipriano AS, a company owned by the chairman of the Board of Directors, Einar J. Greve (the "Underwriters"). The Underwriters will receive an underwriting fee of approximately NOK 5 million in the aggregate from the Company and NOK 3 million in aggregate from the Selling Shareholders, and the Underwriters are guaranteed allocation of offer shares in the Private Placement for an amount corresponding to the lower of (i) 50% of its underwriting obligation in respect of the Private Placement, and (ii) 50% of the number of shares which the guarantor has applied subscription for in the Private Placement. Ferncliff Listed Dai AS has pre-subscribed for NOK 50 million and Cipriano AS has subscribed for NOK 10 million. Completion of the Acquisition, the Private Placement and the Subsequent Offering, is subject to, among other things, approval by the shareholders of the Company at an extraordinary general meeting (the "EGM") which is scheduled for on 14 December 2016. The notice for the EGM will be sent to the shareholders today. The largest shareholders of the Company, including Ferncliff Listed Dai AS, Lars H. Høie, Cipriano AS and Alden AS, have entered into lock-up undertakings until the EGM and have undertaken to vote in favour of such resolutions at the EGM. Following the issuance of the Consideration Shares, the Private Placement and the Subsequent Offering, the Solon Shareholders will own approximately 58 per cent of the Company. The Solon Shareholders have undertaken a lock-up of 12 months to the Managers, subject to certain conditions. The Acquisition of Solon Eiendom is expected to be completed in due course, and as soon as practicably possible following the EGM, i.e. in December 2016. In addition to the foregoing EGM approval of the Acquisition and the Private Placement, the closing of the Acquisition is subject to certain customary closing conditions for transactions of this kind, but the transaction is not subject to regulatory approval. The new Private Placement shares and the Consideration Shares will be issued on a separate ISIN and delivered to the investors, and thereafter converted to the current ISIN of Bionor and become tradable on Oslo Børs as soon as practically possible following the announcement of a prospectus approved by the Norwegian Financial Supervisory Authority which is expected in the first half of January 2017. For more information, please contact: The release is not for publication or distribution, in whole or in part directly or indirectly, in or into Australia, Canada, Japan or the United States (including its territories and possessions, any state of the United States and the District of Columbia). This release is an announcement issued pursuant to legal information obligations, and is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. It is issued for information purposes only, and does not constitute or form part of any offer or solicitation to purchase or subscribe for securities, in the United States or in any other jurisdiction. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "US Securities Act"). The securities may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the US Securities Act. The Company does not intend to register any portion of the offering of the securities in the United States or to conduct a public offering of the securities in the United States. Copies of this announcement are not being made and may not be distributed or sent into Australia, Canada, Japan or the United States. The issue, exercise, purchase or sale of subscription rights and the subscription or purchase of shares in the Company are subject to specific legal or regulatory restrictions in certain jurisdictions. Neither the Company nor the Managers assumes any responsibility in the event there is a violation by any person of such restrictions. The distribution of this release may in certain jurisdictions be restricted by law. Persons into whose possession this release comes should inform themselves about and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction. The Managers are acting for the Company and the Selling Shareholders and no one else in connection with the Private Placement and will not be responsible to anyone other than the Company and the Selling Shareholders for providing the protections afforded to their respective clients or for providing advice in relation to the Private Placement and/or any other matter referred to in this release. Forward-looking statements: This release and any materials distributed in connection with this release may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the Company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements. This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.


News Article | November 24, 2016
Site: globenewswire.com

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANYOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.   BIONOR PHARMA - PRIVATE PLACEMENT SUCCESSFULLY COMPLETED Reference is made to the stock exchange notices on 21 November and 23 November 2016 where Bionor Pharma ASA ("Bionor" or the "Company") announced (1) the acquisition of Solon Eiendom AS ("Solon Eiendom") for a total consideration of approximately NOK 1,000 million (the "Acquisition") to be settled by issuing 6,666,666,666 new shares (the "Consideration Shares") in Bionor at NOK 0.15 per share, (2) a fully underwritten private placement of 1,000,000,000 new shares at NOK 0.15 per share and 1,000,000,000 Consideration Shares at NOK 0.15 per share (the "Private Placement"), and (3) a subsequent offering of 666,666,666 new shares at NOK 0.15 per share directed at existing shareholders of Bionor that does not participate in the Private Placement (the "Subsequent Offering") and who are not resident in a jurisdiction where such offering would be unlawful, or for jurisdictions other than Norway, which would require any filing, registration or similar action. The Private Placement was successfully completed yesterday and a total of 2,000,000,000 shares were agreed to be sold. The Private Placement attracted significant interest from high quality investors and was more than 5 times oversubscribed. Arctic Securities AS, DNB Markets, a part of DNB Bank ASA, and SpareBank 1 Markets AS acted as managers (the "Managers") for the Private Placement and are engaged as managers for the Subsequent Offering. Notification of allotment in the Private Placement will be sent to the applicants today through a notification to be issued by the Managers. The payment date is on or about 19 December 2016 and expected delivery date is on or about 21 December 2016. The new Private Placement shares and the Consideration Shares will be issued on a separate ISIN and delivered to the investors, and thereafter converted to the current ISIN of Bionor Pharma and become tradable on Oslo Børs as soon as practically possible following the announcement of a prospectus approved by the Norwegian Financial Supervisory Authority which is expected in the first half of January 2017, subject to approval at the extraordinary general meeting (the "EGM") which is scheduled for on 14 December 2016. The Company will receive gross proceeds of NOK 150 million from the Private Placement when completed. The net proceeds from the Private Placement will be used for acquisition of a minority stake currently owned by Edvin Austbø (who is an indirect shareholder of Solon Eiendom) in a property project in Ski for approximately NOK 60 million, acquisition of land for new projects and for general corporate purposes. Cipriano AS, a company wholly owned by Einar J. Greve, Chairman of Bionor, was conditionally allocated 66,666,667 shares in the Private Placement. Einar J. Greve, through Cipriano AS, currently holds 50,000,000 shares in Bionor. Ferncliff Listed Dai AS, a company indirectly controlled by Øystein Stray Spetalen, Board member of Bionor, was conditionally allocated 183,333,333 shares in the Private Placement. Ferncliff Listed Dai AS currently holds 270,000,000 shares in Bionor. Certain existing shareholders of Solon Eiendom have conditionally sold down 1,000,000,000 Consideration Shares at NOK 0.15 per share as part of the Private Placement. Dukat AS (owned by Tore Aksel Voldberg), MRD Holding AS (owned by Simen Thorsen) and Solon AS (owned by Tore Aksel Voldberg) have agreed to sell 333,333,333, 333,333,334 and 333,333,333 Consideration Shares, respectively. The existing shareholders in Solon Eiendom are subject to a 12 months lock-up following completion of the Private Placement. The Board has assessed the Private Placement in light of the equal treatment requirement, balanced the considerations that speak for and against carrying out the Private Placement and concluded that the waiver of the preferential rights inherent in a private placement was considered necessary in the interest of time and successful completion in the common interest of the Company and its shareholders. Completion of the Acquisition, the Private Placement and the Subsequent Offering, is still subject to, among other things, approval by the shareholders of the Company at the EGM which is scheduled for on 14 December 2016. The largest shareholders of the Company, including Ferncliff Listed Dai AS, Lars H. Høie, Cipriano AS and Alden AS, have entered into lock-up undertakings until the EGM and have undertaken to vote in favour of such resolutions at the EGM. Subsequent to the completion of the Private Placement and Acquisition, the Company plans to carry out a Subsequent Offering of 666,666,666 new shares at NOK 0.15 per share directed at existing shareholders of Bionor who did not receive allocation of shares in the Private Placement or who participated in the underwriting consortium for the Private Placement, provided that such shareholders are not resident in a jurisdiction where such offering would be unlawful, or would (in jurisdictions other than Norway) require any prospectus filing, registration or similar action. The Company intends to seek listing for the subscription rights for the Subsequent Offering. The subscription period for the Subsequent Offering will commence after approval of a prospectus by the Norwegian Financial Supervisory Authority which is expected in the first half of January 2017. The Company will provide additional information about the Subsequent Offering in due course. The last day the Bionor shares traded including the right to participate in the conditional Subsequent Offering was 23 November 2016, and the Bionor shares will trade exclusive the right to participate in the conditional Subsequent Offering from today. The record date is 25 November 2016. For more information, please contact: Einar J. Greve Chairman of the Board, Bionor Pharma ASA E-mail: ejg@cipriano.no Cell Phone: +47 900 27 766 The release is not for publication or distribution, in whole or in part directly or indirectly, in or into Australia, Canada, Japan or the United States (including its territories and possessions, any state of the United States and the District of Columbia). This release is an announcement issued pursuant to legal information obligations, and is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. It is issued for information purposes only, and does not constitute or form part of any offer or solicitation to purchase or subscribe for securities, in the United States or in any other jurisdiction. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "US Securities Act"). The securities may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the US Securities Act. The Company does not intend to register any portion of the offering of the securities in the United States or to conduct a public offering of the securities in the United States. Copies of this announcement are not being made and may not be distributed or sent into Australia, Canada, Japan or the United States. The issue, exercise, purchase or sale of subscription rights and the subscription or purchase of shares in the Company are subject to specific legal or regulatory restrictions in certain jurisdictions. Neither the Company nor the Managers assumes any responsibility in the event there is a violation by any person of such restrictions. The distribution of this release may in certain jurisdictions be restricted by law. Persons into whose possession this release comes should inform themselves about and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction. The Managers are acting for the Company and the Selling Shareholders and no one else in connection with the Private Placement and will not be responsible to anyone other than the Company and the Selling Shareholders for providing the protections afforded to their respective clients or for providing advice in relation to the Private Placement and/or any other matter referred to in this release. Forward-looking statements: This release and any materials distributed in connection with this release may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the Company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.


News Article | November 24, 2016
Site: globenewswire.com

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANYOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Reference is made to Bionor Pharma ASA's ("Bionor" or the "Company") announcement regarding a successfully completed Private Placement and a contemplated fully underwritten Subsequent Offering published earlier today. The Private Placement and Subsequent Offering are conditional upon approval by the shareholders in an extraordinary general meeting (the "EGM") to be held on 14 December 2016. The Board has proposed to conduct a Subsequent Offering to existing shareholders who were not allocated shares in the Private Placement nor participated in the underwriting consortium, provided that such shareholders are not resident in a jurisdiction where such offering would be unlawful, or would (in jurisdictions other than Norway) require any prospectus filing, registration or similar action. The Subsequent Offering is inter alia subject to approval by the EGM, completion of the Company's acquisition of Solon Eiendom AS and the Private Placement and a prospectus being approved by the Norwegian Financial Supervisory Authority and published by the Company. Key information in relation to the conditional subsequent offering: Date on which the terms and conditions of the rights offering were announced 21 November 2016 Last day including right 23 November 2016 Ex-date 24 November 2016 Record date 25 November 2016 Date of approval 14 December 2016 Maximum number of new shares in the subsequent offering 666,666,666 new shares Subscription price NOK 0.15 per share Shall the rights be listed yes/no Yes This information is published in accordance with the requirements of the Continuing Obligations.


News Article | December 15, 2016
Site: globenewswire.com

SOLON EIENDOM ASA - ELECTION OF NEW BOARD OF DIRECTORS AND APPOINTMENT OF NEW CEO AND CFO (Oslo, Norway, 15 December 2016) Reference is made to the stock exchange announcement by Bionor Pharma ASA (now Solon Eiendom ASA) (the "Company", ticker "BIONOR") earlier today regarding a completed extraordinary general meeting of the Company and the stock exchange announcement earlier today regarding completion of the acquisition of the entire share capital of Solon Eiendom AS. With effect from today, the new Board of Directors of the Company will consist of: - Simen Thorsen, chairman - Einar J. Greve, deputy chairman - Tore Aksel Voldberg, board member - Bente Bøhler, board member - Katarina Finneng, board member The new Board of Directors was elected by the shareholders at the extraordinary general meeting held yesterday, 14 December 2016. Further, the Board of Directors of the Company has appointed Mr. Andreas Martinussen as the Company's Chief Executive Officer (CEO) and Mr. Tarjei Røise Warholm as the Company's Chief Financial Officer (CFO).  They will both take over the responsibilities as CEO and CFO as of today. With effect as of the same date, Unni Hjelmaas will be appointed as CEO of Bionor Immuno AS (a wholly owned subsidiary of the Company). For further information please contact: Simen Thorsen (Chairman) st@soloneiendom.no / 91 886 886 This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.


News Article | February 28, 2017
Site: globenewswire.com

(Oslo, Norway, 28 February 2017) Solon Eiendom ASA (OSE:SOLON) is proud to present its first quarterly report (Q4 2016) as a listed company on the Oslo Stock Exchange after the reverse acquisition of Bionor Pharma ASA in December 2016. "2016 was the best year in the company's history with all time high activity in terms of sales. Housing prices in the Oslo area continue to increase which is having a positive impact on our results," says Andreas Martinussen CEO at Solon Eiendom ASA. "This reflects our strategy, where a significant portion of our costs are fixed up front and a majority of the homes are sold before construction starts. When the sales prices of homes increase, the profitability of our projects improves." Solon Eiendom sold 35 homes for NOK 323 million in the fourth quarter of 2016. Increase in the housing market led to an improved profit margin. At year-end 2016, Solon Eiendom had 259 units under construction of which 82% were sold. "We have a positive outlook for our market. In the Oslo area, where we have the majority of our projects, demand is high and supply low." says Martinussen. HIGHLIGHTS Q4 2016 and 2016 - Revenue increased 36% in Q4 2016 compared to Q4 2015 - All-time high sales in 2016 of NOK 975 million of which NOK 323 million in Q4 - 146 units sold in 2016 including 35 units in Q4 - The number of units delivered in Q4 and for 2016 was 8 and 113 respectively - The total number of units in production end Q4 amounted to 259 - Real estate segment 2016 EBITDA increased 10,8% from NOK 117 million to NOK 130 million - Land bank acquisitions in 2016 of NOK 275 million - A share issue of gross NOK 150 million - The board will propose a dividend of NOK 50 000 000 for 2016 which is dependent on the approval at an extraordinary shareholders meeting of a share capital reduction. EVENTS AFTER THE BALANCE SHEET DATE - A share issue of gross NOK 100 million in January 2017. - Scott Danielsen appointed as CFO For further information, please contact: Andreas Martinussen, Chief Executive Officer, Solon Eiendom ASA Telephone:     +47 400 00 405, email:  am@soloneiendom.no About Solon Eiendom ASA Solon Eiendom ASA is a residential real estate developer controlling the entire value chain from acquisition of land, construction through to marketing and sale of homes. The Company focuses on developing residential real estate projects in the greater Oslo region. The full property portfolio potential of the Company, including projects under development and the land bank combined, amounts to approximately 1,900 residential units. The company is headquartered in Oslo. Please visit our website: www.soloneiendom.no This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.


News Article | December 16, 2016
Site: globenewswire.com

As from December 19, 2016, Bionor Pharma ASA will be listed under its new company name, Solon Eiendom ASA. For further information concerning this exchange notice please contact Elin Nygren or Johan Önneberg +46 8 405 60 00, or iss@nasdaqomx.com


News Article | December 15, 2016
Site: globenewswire.com

Reference is made to the announcement by Bionor Pharma ASA on 14 December 2016 regarding completion of EGM. Upon issuance of the Consideration Shares, the shares in the Private Placement and the shares in the Subsequent Offering, Lars H. Høie will hold 128,973,522 shares and votes in the Company, corresponding to 1.33% of the total share capital and votes of the Company. This information is subject to the disclosure requirements set out in section 4-3 of the Norwegian Securities Trading Act.


News Article | December 13, 2016
Site: globenewswire.com

Reference is made to the announcement on 1 December 2016 regarding exercise of warrants. The share capital of the Company was increased by NOK 862.40 as a consequence of the warrant exercise. The new share capital of the Company has now been registered in the Company Register (Foretaksregisteret). The Company's new share capital is NOK 138,567,772.10 divided into 1,385,677,721 shares with a par value of NOK 0.10. This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. Further information Einar J. Greve Chairman of the Board, Bionor Pharma ASA E-mail: ejg@cipriano.no, Cell Phone: +47 900 27 766


News Article | December 1, 2016
Site: globenewswire.com

BIONOR PHARMA ASA STOCK EXCHANGE ANNOUNCEMENT (Oslo, Norway, 23 November 2016)   Reference is made to the resolution by the EGM on 11 February 2016 to issue warrants to participants in the private placement and subsequent offering completed on 10 March 2016. The exercise price for the warrants is NOK 0.71 per share. The warrants expired on 30 November 2016. The Company received exercise of a total of 8624 warrants within the expiry of the exercise period and will accordingly proceed to issue 8,624 new shares at a subscription price of NOK 0.71 per share. The share capital of the Company will be increased by NOK 862.40 as a consequence of the warrant exercise. This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.   Further information Einar J. Greve Chairman of the Board, Bionor Pharma ASA E-mail: ejg@cipriano.no Cell Phone: +47 900 27 766 Unni Hjelmaas Acting Chief Executive Officer, Bionor Pharma ASA E-mail: uh@bionorpharma.com Cell Phone: +47 915 19 651

Loading Bionor Pharma collaborators
Loading Bionor Pharma collaborators